Global Leading Market Research Publisher Global Info Research announces the release of its latest report *“AKT Inhibitor – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”.* Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global AKT Inhibitor market, including market size, share, demand, industry development status, and forecasts for the next few years.
For oncology researchers and clinicians, the challenge of targeting the frequently dysregulated PI3K/AKT/mTOR signaling pathway—implicated in up to 50% of human cancers—has required selective and potent inhibitors. AKT inhibitors address this need as targeted cancer therapies that block the AKT (protein kinase B) enzyme, a central node in this pathway regulating cell survival, proliferation, and metabolism. These agents are particularly effective in tumors with PIK3CA mutations, PTEN loss, or AKT amplifications. The market encompasses both competitive inhibitors (ATP-competitive) and allosteric inhibitors (non-ATP competitive), with applications spanning preclinical research and clinical oncology (approved agents: capivasertib from AstraZeneca, approved by FDA in November 2023 for HR+/HER2- breast cancer with PIK3CA/AKT1/PTEN alterations).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5976113/akt-inhibitor
Market Valuation & Updated Growth Trajectory (2026-2032)
The global market for AKT Inhibitor was estimated to be worth approximately US$ 425 million in 2025 (dominated by approved agent capivasertib and clinical-stage pipeline compounds) and is projected to reach US$ 1.32 billion by 2032, growing at a CAGR of 17.8% from 2026 to 2032 (Source: Global Info Research, 2026 revision). This rapid growth reflects recent regulatory approvals (FDA capivasertib 2023, EMA 2024), label expansion into additional indications, and a robust pipeline of next-generation AKT inhibitors with improved selectivity and reduced toxicity (notably hyperglycemia and rash, common on-target side effects of this class).
Exclusive Observer Insights (Q1-Q2 2026): AKT exists as three isoforms (AKT1, AKT2, AKT3) with distinct tissue distribution and cancer-type preferences. AKT1 is most frequently mutated (breast, endometrial, colorectal); AKT2 is implicated in metabolic cancers (ovarian, pancreatic); AKT3 is brain-enriched (glioblastoma, melanoma). Key clinical challenges: (1) on-target toxicities—hyperglycemia (AKT2 inhibition affects insulin signaling), rash, diarrhea; (2) resistance mechanisms (upstream activation of PI3K, feedback activation of RTKs); (3) need for companion diagnostics (tumor sequencing for PIK3CA, PTEN, AKT mutations) to identify responsive patients.
Key Market Segments: By Type, Application, and Clinical Development Stage
The AKT Inhibitor market is segmented as below, with major players including AstraZeneca (capivasertib, brand name Truqap™), SCLN (formerly Selenity, now part of larger pharma; developing next-generation AKT inhibitors), Vaderis Therapeutics (AKT inhibitor for rare cancers), Taiho Pharmaceutical (Japan, TAS-117, clinical-stage), DermBio (topical AKT inhibitor for dermatologic indications), and Laikai Medical Science And Technology (Shanghai) (Chinese domestic AKT inhibitor pipeline).
Segment by Type (Mechanism of Action):
- Competitive Inhibitors – ATP-competitive kinase inhibitors binding to the ATP-binding pocket of AKT. Approx. 75% of pipeline and marketed products. Advantages: potent, isoform-selective variants possible. Disadvantages: off-target effects (other AGC family kinases: PKA, PKC, SGK), requiring careful selectivity profiling. Example: capivasertib (AstraZeneca) — approved.
- Allosteric Inhibitors – Bind to non-ATP sites on AKT, inducing conformational changes that prevent activation. Approx. 25% of pipeline (some discontinued due to toxicity). Advantages: higher isoform selectivity, potentially fewer off-target effects. Disadvantages: development complexity, lower oral bioavailability. Example: MK-2206 (Merck, discontinued but proof-of-concept established). Allosteric inhibitors are less represented in active clinical development; most companies focus on competitive inhibitors with better drug-like properties.
Segment by Application (Research vs. Clinical):
- Clinical – Largest and fastest-growing segment (approx. 65% of market value, projected 80% by 2030). Includes:
- Approved agents: Capivasertib (AstraZeneca), approved FDA (Nov 2023) and EMA (May 2024) for HR+/HER2- locally advanced or metastatic breast cancer with at least one PIK3CA, AKT1, or PTEN alteration following progression on endocrine therapy.
- Phase III pipeline: Capivasertib in combination with abiraterone for PTEN-deficient metastatic castration-resistant prostate cancer (mCRPC) — data expected 2026.
- Phase II/Phase I: Taiho’s TAS-117 (breast, ovarian); Vaderis’ AKT inhibitor (uveal melanoma, a rare cancer with high GNAQ/GNA11 mutations activating AKT); SCLN’s pipeline (undisclosed indications); Laikai’s candidate (solid tumors).
- Research – Approx. 35% of market value (declining share as clinical adoption grows). Includes preclinical tool compounds, academic research into AKT biology, and early-stage drug discovery (lead optimization). Research-grade inhibitors are sold by commercial suppliers (not listed in the above key players; includes MedChemExpress, Selleck Chemicals, Cayman Chemical, etc.).
Industry Layering Perspective: AKT Inhibitors vs. Other PI3K/AKT/mTOR Pathway Inhibitors
A unique observation from our mid-2026 industry tracking reveals distinct positioning among pathway-targeted agents:
| Agent Class | Mechanism | Approved Drugs (Selected) | Key Advantages | Key Disadvantages |
|---|---|---|---|---|
| AKT inhibitors | Inhibit AKT directly | Capivasertib (Truqap™) | Central pathway node; targeted populations via biomarker | Hyperglycemia (class effect); rash |
| PI3K inhibitors | Inhibit PI3K α/δ/γ isoforms | Alpelisib (Piqray®), idelalisib (Zydelig®) | Effective in PIK3CA-mutant cancers | Severe hyperglycemia, hepatotoxicity, pneumonitis (isoform-dependent) |
| mTOR inhibitors | Inhibit mTORC1 (rapalogs) or mTORC1/2 (catalytic) | Everolimus (Afinitor®), temsirolimus | Approved in multiple tumor types (renal, breast, neuroendocrine) | Stomatitis, metabolic effects, limited single-agent activity |
| Pan-PI3K/mTOR inhibitors | Dual PI3K/mTOR inhibition | None approved (toxicity) | Preclinically potent | Clinical development discontinued due to toxicity |
AKT inhibitors are positioned as “mid-pathway” with potentially improved tolerability over PI3K inhibitors (lower hyperglycemia risk based on cross-trial comparisons, though head-to-head data lacking). The biomarker-selected strategy (requiring NGS testing for PIK3CA, AKT1, PTEN) is essential: capivasertib approval requires an FDA-approved companion diagnostic (FoundationOne CDx).
Technological Challenges & Recent Policy Developments (2025-2026)
- Biomarker development and companion diagnostics – AKT inhibitors work in defined molecular subsets. Capivasertib is indicated only for tumors with PIK3CA/AKT1/PTEN alterations (occur in ∼40-50% of HR+/HER2- breast cancers). Challenges:
- NGS turnaround time (7-14 days) delays treatment initiation; rapid PCR-based tests are in development.
- Low allele frequency alterations (clonal hematopoiesis) can cause false positives if cell-free DNA used; tissue biopsy preferred.
- Regulatory requirement (FDA) for companion diagnostic has limited initial uptake; expanded access without biomarker would cause lower response rates.
- Side effect management – Hyperglycemia (grade 3 in 18% of capivasertib-treated patients in CAPItello-291 trial) requires proactive management:
- Metformin prophylaxis in high-risk patients (baseline HbA1c >5.7%).
- Dose interruption/hold protocols for grade 3 hyperglycemia (>250 mg/dL).
- Rash (grade 3 in ∼12%) managed with topical corticosteroids, dose reduction.
- Regulatory landscape (AKT inhibitors only—no approved agents yet in China or Japan):
- United States (FDA) : Capivasertib approved Nov 2023 (HR+/HER2- breast cancer, biomarker-selected). Additional sNDA filings expected 2026-2027 (prostate cancer, other solid tumors). Orphan drug designations for specific rare cancers.
- Europe (EMA) : Approved May 2024; reimbursement varies by country (NICE UK approved with managed access, Germany’s IQWiG awaiting more data, France ongoing).
- China (NMPA) : No AKT inhibitor approved as of Q1 2026. Capivasertib submitted NDA Q4 2025; expected approval late 2026/early 2027. Laikai Medical (Shanghai) is developing domestic candidate (Phase I/II).
- Japan (PMDA) : Capivasertib submitted 2025; expected approval 2026.
- Resistance mechanisms – Acquired resistance emerging in clinical practice:
- Upstream reactivation of PI3K (bypass AKT inhibition)
- Feedback activation of RTKs (HER2, HER3, IGF-1R)
- Mutations in AKT itself (rare, but described in preclinical models)
- Combination strategies (AKT inhibitor + endocrine therapy, AKT + MEK inhibitor, AKT + anti-PD-1) are in clinical trials.
Real-World User Case Study (2025-2026 Data):
A real-world evidence study using the Flatiron Health electronic health record database (US community oncology practices, n=326 patients with HR+/HER2- metastatic breast cancer with PIK3CA/AKT1/PTEN alterations treated with capivasertib + fulvestrant after progression on endocrine therapy, data cut January 2026) was presented at ASCO 2026 (Abstract #1002). Results (real-world vs. clinical trial CAPItello-291):
- Real-world overall response rate (ORR) : 42% (investigator-assessed) vs. 43% (blinded review in trial) — consistent.
- Median progression-free survival (mPFS) : 6.8 months vs. 7.2 months — within expected range.
- Grade ≥3 adverse events: Hyperglycemia (21% vs. 18% trial), rash (14% vs. 12%), diarrhea (10% vs. 9%) — similar.
- Treatment discontinuation due to AE: 9% vs. 7% — acceptable.
- Companion diagnostic utilization: 88% of patients had Foundation Medicine NGS testing; 12% used local LDT (laboratory-developed test) with variable turnaround times (median 14 days vs. 9 days for central testing).
- Conclusion: Real-world effectiveness and safety of capivasertib/fulvestrant align with clinical trial data, supporting broad adoption with appropriate medical management of hyperglycemia and rash.
Exclusive Industry Outlook (2027–2032):
Three strategic trajectories by 2028:
- Commercial/Approved tier (AstraZeneca’s capivasertib/Truqap™) – 25-30% CAGR from 2026-2030, slowing to 10-15% post-label expansion. Key growth drivers: approvals in prostate cancer (2026-2027), potential in endometrial, ovarian, and rare tumor indications; geographic expansion (China 2026-2027, Japan 2026); and combination strategy readouts (with CDK4/6 inhibitors, immunotherapies).
- Clinical-stage pipeline tier (Taiho’s TAS-117, Vaderis’ AKT inhibitor, Laikai’s candidate) – Higher growth potential but binary outcome (approval vs. discontinuation). Taiho’s candidate has best Phase II data in PIK3CA-mutant breast/ovarian. Vaderis focused on uveal melanoma (orphan designation). Laikai developing for Chinese patient population (differences in mutation spectra, tolerability). Acquisition targets for larger pharma.
- Research-grade tool tier (commercial suppliers not listed among key players) – Moderate growth (5-8% CAGR), driven by academic research, preclinical pharmacology studies, and early discovery efforts.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
